Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: StemCells, Inc. is a biopharmaceutical company focused on developing stem and progenitor cell therapies for degenerative diseases, including Parkinson's, Alzheimer's, liver failure, and diabetes. The company utilizes tissue-derived cells (fetal or adult) rather than embryonic stem cells. As of the reporting date, the company has no commercial products and is in the preclinical stage of development for its neural and liver programs.
Key Financial Metrics
| Metric | 2002 | 2001 | 2000 |
|---|---|---|---|
| Total Revenue | $415,377 | $805,231 | $74,300 |
| Net Loss (Common Shareholders) | $(11,645,057) | $(4,992,414) | $(11,606,477) |
| Loss Per Share (Basic/Diluted) | $(0.46) | $(0.22) | $(0.58) |
| Research & Development Expenses | $6,400,199 | $8,603,444 | $5,979,007 |
| General & Administrative Expenses | $4,225,256 | $3,787,759 | $3,361,231 |
| Cash and Cash Equivalents (Year End) | $4,236,367 | $13,697,195 | $6,068,947 |
| Long-Term Debt (Capital Leases) | $2,086,667 | $2,315,833 | $2,605,000 (approx) |
| Stockholders' Equity | $3,787,571 | $13,207,807 | $21,698,772 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 48% from $805,000 in 2001 to $415,000 in 2002. This was primarily due to the absence of a one-time $300,000 receipt from the assignment of rights to Modex Therapeutics in 2001 and a decrease in grant revenue.
- Increased Net Loss: Net loss applicable to common shareholders increased significantly to $11.6 million in 2002 compared to $5.0 million in 2001. The 2001 loss was artificially reduced by a $7.8 million realized gain from the sale of Modex Therapeutics shares, which did not recur in 2002.
- Cost Reduction Initiative: In September 2002, the company implemented a cost reduction program, reducing workforce and annualized expenses by approximately 25% to focus resources on preclinical development of neural and liver therapies.
- Cash Burn: Cash and cash equivalents dropped by approximately $9.5 million during 2002, reflecting a net cash used in operating activities of $10.1 million.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Crisis: Management explicitly states that existing capital resources are not sufficient to fund operations through the end of the second quarter of 2003. The company requires significant additional capital to sustain product development.
- Going Concern: The independent auditors (Ernst & Young LLP) issued a report with a "going concern" qualification, noting that the company's history of losses and negative cash flows raise substantial doubt about its ability to continue operations without additional financing.
- Facility Obligations: The company faces ongoing lease and operating costs of approximately $1 million for 2003 related to former facilities in Rhode Island, net of sublease income. Failure to sublease or sell these properties could materially adversely affect liquidity.
- Regulatory Path: Products are subject to rigorous FDA regulation. The company has not yet submitted an Investigational New Drug (IND) application for its stem cell therapies.
- Intellectual Property: The company relies on a portfolio of patents and licenses (e.g., from NeuroSpheres, Cal Tech, Scripps). There is a risk that third-party patents could block commercialization or that the company's own patents may not provide adequate protection.
Investor Verification Checklist
- Runway Verification: Confirm the company's ability to secure financing before the end of Q2 2003 to avoid bankruptcy proceedings.
- Facility Disposal: Verify progress on subleasing or selling the Rhode Island facilities to reduce the $1 million annual operating burden.
- Grant Renewals: Monitor the status of NIH grants (SBIR and NIDDK), which provided $375,000 of revenue in 2002, as they are subject to renewal and satisfactory progress.
- Preferred Stock Redemption: Review the terms of the $4 million 3% Cumulative Convertible Preferred Stock, which has a mandatory redemption date of December 4, 2003.
- Stock Dilution: Assess the impact of the $30 million equity line with Sativum Investments Limited and outstanding options/warrants on future share count.